The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses real-world outcomes of dose modifications of the first-generation BTK inhibitor (BTKi) ibrutinib in first-line treatment of patients with Waldenström’s macroglobulinemia (WM). Dr Castillo highlights that dose reductions do not impact patient outcomes, suggesting that this is a feasible method to manage toxicities while sustaining the therapeutic benefits of ibrutinib. Data on dose reduction of second-generation BTKi’s, such as acalabrutinib and zanubrutinib, is needed. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Mustang Bio, Kite, Loxo, Abbvie
Research Funding: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Loxo, Abbvie
